AstraZeneca PLC (AZN)vsTango Therapeutics Inc (TNGX)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
TNGX
Tango Therapeutics Inc
$20.98
-2.96%
HEALTHCARE · Cap: $3.18B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 94057% more annual revenue ($58.74B vs $62.38M). AZN leads profitability with a 17.4% profit margin vs -162.9%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
TNGX
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+21.7%
Fair Value
$16.11
Current Price
$20.98
$4.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Trading at 8.2x book value
0.0% earnings growth
ROE of -37.2% — below average capital efficiency
Revenue declined 100.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : TNGX
TNGX has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : TNGX
The primary concerns for TNGX are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while TNGX is a turnaround play — different risk/reward profiles.
TNGX carries more volatility with a beta of 1.31 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 20/100), backed by strong 17.4% margins. TNGX offers better value entry with a 21.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Tango Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tango Therapeutics Inc. is a clinical-stage biotechnology firm focused on revolutionizing cancer treatment through targeted therapies based on the principle of synthetic lethality. With a robust and diverse pipeline of innovative drug candidates, the company is poised to make significant strides in precision oncology. Tango is committed to enhancing its research capabilities through strategic partnerships with esteemed academic institutions, further solidifying its role as a leader in advancing treatment paradigms in oncology. Through its visionary approach, Tango aims to address critical unmet needs in cancer care and significantly improve patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?